Abstract:Patients with chronic pain often develop comorbid depressive symptoms, which makes the pain symptoms more complicated and refractory. However, the underlying mechanisms are poorly known. Here, in a repeated complete Freund's adjuvant (CFA) male mouse model, we reported a specific regulatory role of the paraventricular thalamic nucleus (PVT) glutamatergic neurons, particularly the anterior PVT (PVA) neurons, in mediating chronic pain and depression comorbidity (CDC). Our c-Fos protein staining observed increased PVA neuronal activity in CFA-CDC mice. In wild-type mice, chemogenetic activation of PVA glutamatergic neurons was sufficient to decrease the 50% paw withdrawal thresholds (50% PWTs), while depressive-like behaviors evaluated with immobile time in tail suspension test (TST) and forced swim test (FST) could only be achieved by repeated chemogenetic activation. Chemogenetic inhibition of PVA glutamatergic neurons reversed the decreased 50% PWTs in CFA mice without depressive-like symptoms and the increased TST and FST immobility in CFA-CDC mice. Surprisingly, in CFA-CDC mice, chemogenetically inhibiting PVA glutamatergic neurons failed to reverse the decrease of 50% PWTs which could be restored by rapid-onset antidepressant S-ketamine. Further behavioral tests in chronic restraint stress mice and CFA pain mice indicated that PVA glutamatergic neuron inhibition and S-ketamine independently alleviate sensory and affective pain. Molecular profiling and pharmacological studies revealed the 5-hydroxytryptamine receptor 1D (Htr1d) in CFA pain-related PVT engram neurons as a potential target for treating CDC. These findings identified novel CDC neuronal and molecular mechanisms in the PVT and provided insight into the complicated pain neuropathology under a comorbid state with depression and related drug development. Significance Statement Patients with chronic pain frequently experience concurrent depressive symptoms, which complicates the treatment of the pain symptoms. Recently, the paraventricular thalamic nucleus (PVT) has attracted growing interest in modulating animal behaviors of pain sensation and stress-related affective disorders. However, whether and how PVT mediate chronic pain and depression comorbidity (CDC) remains poorly understood. Here, utilizing chemogenetics, viral labelling, neuronal cell types-based TRAP (translating ribosome affinity purification) technology and pharmacological studies, our current study revealed that PVT is a central hub for regulating sensory pain and depressive-like behaviors but not affective pain by functioning through the 5-hydroxytryptamine receptor 1D (Htr1d). These findings provide new insights of the regulatory role of the PVT and a potential molecular target for future analgesic development.

DNMT1 mediates chronic pain-related depression by inhibiting GABAergic neuronal activation in central amygdala

LncRNA XR_351665 Contributes to Chronic Pain-Induced Depression by Upregulating DNMT1 via Sponging miR-152-3p

Correction: Divergent Modulation of Pain and Anxiety by GABAergic Neurons in the Ventrolateral Periaqueductal Gray and Dorsal Raphe.

Contribution of DNA methyltransferases to spared nerve injury induced depression partially through epigenetically repressing Bdnf in hippocampus: Reversal by ketamine

Contribution of DNMT1 to Neuropathic Pain Genesis Partially Through Epigenetically Repressing Kcna2 in Primary Afferent Neurons.

Spinal Cord DNMT1 Contributes to Diabetic Neuropathic Pain Mediated by Mir-152-3p Downregulation

DNMT3a Downregulation Ttriggered Upregulation of GABAA Receptor in the mPFC Promotes Paclitaxel‐Induced Pain and Anxiety in Male Mice

[Role of DNA Methyltransferases in the Pathogenesis of Neuropathic Pain in Rats].

Dna Methyltransferase Dnmt3a Contributes to Neuropathic Pain by Repressing Kcna2 in Primary Afferent Neurons

Specific inhibition of TET1 in the spinal dorsal horn alleviates inflammatory pain in mice by regulating synaptic plasticity

Targeting GATA1 and p2x7r Locus Binding in Spinal Astrocytes Suppresses Chronic Visceral Pain by Promoting DNA Demethylation

DNA N6-methyladenine methylase N6AMT1 controls neuropathic pain through epigenetically modifying Kcnj16 in dorsal horn neurons

Pain vulnerability and DNA methyltransferase 3a involved in the affective dimension of chronic pain.

DNA Methylation: A Target in Neuropathic Pain

TIAM1-mediated synaptic plasticity underlies comorbid depression–like and ketamine antidepressant–like actions in chronic pain

ZEB1 Induces Ddr1 Promoter Hypermethylation and Contributes to the Chronic Pain in Spinal Cord in Rats Following Oxaliplatin Treatment

Tiam1-mediated synaptic plasticity drives comorbid depressive symptoms in chronic pain

SIRT1 Decreases Emotional Pain Vulnerability with Associated CaMKIIα Deacetylation in Central Amygdala.

METTL14-mediated m6A epitranscriptomic modification contributes to chemotherapy-induced neuropathic pain by stabilizing GluN2A expression via IGF2BP2

Dysfunctional S1P/S1PR1 signaling in the dentate gyrus drives vulnerability of chronic pain-related memory impairment

Neuronal and molecular mechanisms underlying chronic pain and depression comorbidity in the paraventricular thalamus